

Serial No.: 10/679,217  
Inventor(s): Mannion et al.

U.S. PTO Customer No. 25280  
Case No.: 5646

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Mannion et al.

Serial Number: 10/679,217

Filed: October 3, 2003

For: **NUCLEATING ADDITIVE FORMULATIONS OF BICYCLO[2.2.1]  
HEPTANE DICARBOXYLATE SALTS**

Group Art Unit: 1713

Examiner: Not Yet Assigned

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Certificate of Mailing Under 37 CFR § 1.8**

I hereby certify that this correspondence, and all correspondence referenced herein as being enclosed with this correspondence, is being deposited with the United States Postal Service in an envelope addressed to "Commissioner for Patents, PO Box 1450, Alexandria VA 22313-1450" with sufficient postage on the following

date: April 5, 2004

Signature: Kerry A. Lawter

Name: Kerry A. Lawter

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Applicant hereby submits this Information Disclosure Statement filed according to the provisions of 37 CFR §1.97 and §1.98. Enclosed herewith is Form PTO-1449 (Modified) which lists various references (copies enclosed) submitted by Applicant for consideration.

References for which copies already have been provided in a previous parent application to which this application claims priority pursuant to 37 CFR §1.98 (d) need not be submitted, and are indicated by an asterisk. Copies of US patent references also are not enclosed, due to the rule change regarding submitting US patent references.

The Examiner is requested to review each of the references, indicate that the references were reviewed by initialing and returning a copy of the initialed Form to Applicant.


This information disclosure statement is being submitted within three months of the filing date of the application, within three months of the date of entry of the national stage, in connection with a newly filed RCE, or prior to the mailing date of a first Office Action on the merits.

Serial No.: 10/679,217  
Inventor(s): Mannion et al.

U.S. PTO Customer No. 25280  
Case No.: 5646


However, even if none of the three conditions above apply, the Examiner is requested to consider this Information Disclosure Statement under 37 CFR §1.97(c)(2) and the Commissioner is hereby authorized to withdraw the fee set forth in 37 CFR §1.17(p) from Deposit Account 04-0500.

Respectfully Submitted,



John E. Vick, Jr.  
Reg. No. 33,808

MILLIKEN & COMPANY  
920 Milliken Road, M-495  
Spartanburg, SC 29303  
(864) 503-1383



Form PTO-1449 (Modified)

INFORMATION DISCLOSURE STATEMENT  
IN A PATENT APPLICATION

Sheet 1 of 4.

Serial No.: 10/679,217

Filing Date: October 3, 2003

Inventor(s): Mannion et al.

Group Art Unit: 1713

Examiner: Unknown

US PTO Customer No: 25280

Case No.: 5646

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	IDENTIFIER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS
	AA	3,201,363	08/1965	Spurlin et al.	260	30.4
	AB	3,207,736	09/1965	Wijga et al.	260	93.7
	AC	3,234,233	02/1966	Bolger et al.	260	326
	AD	3,320,267	05/1967	Poos et al.	260	295
	AE	3,367,926	02/1968	Voeks et al.	260	93.5
	AF	3,527,736	09/1970	Averink et al.	260	78.4
	AG	3,793,401	02/1974	Nield et al.	260	876
	AH	3,829,450	08/1974	Schmerling et al.	260	346.3
	AI	3,873,643	03/1975	Wu et al.	260	878
	AJ	3,882,194	05/1975	Krebaum et al.	260	878
	AK	3,928,687	12/1975	Wada et al.	428	461
	AL	3,933,779	01/1976	Baron et al.	260	93.5
	AM	3,941,746	03/1976	Stephen et al.	260	45.8
	AN	3,954,913	05/1976	Uebele et al.	260	880
	AO	4,039,491	08/1977	Ikeda et al.	260	875
	AP	4,134,895	01/1979	Roth et al.	260	326
	AQ	4,134,927	01/1979	Tomoshige et al.	260	878
	AR	4,452,942	06/1984	Shida et al.	525	74
	AS	4,476,184	10/1984	Lubowitz et al.	428	288
	AT	4,503,219	03/1985	Reffert et al.	528	481
	AU	4,704,421	11/1987	Teskin et al.	524	287
	AV	4,739,017	04/1988	Tabor et al.	525	300
	AW	4,778,837	10/1988	Waterman et al.	524	89

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) <b>INFORMATION DISCLOSURE STATEMENT IN A PATENT APPLICATION</b> Sheet <u>4</u> of <u>4</u> .	Serial No.: 10/679,217	Filing Date: October 3, 2003
	Inventor(s): Mannion et al.	
	Group Art Unit: 1713	Examiner: Unknown
	US PTO Customer No: 25280	Case No.: 5646

#### OTHER DOCUMENTS

EXAMINER INITIALS	IDENTIFIER	INCLUDE: AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	BX	H.N. Beck, "Heterogeneous Nucleating Agents of Polypropylene Crystallization", Journal of Applied Polymer Science, vol. 11, pp. 673-685, 1967
	BY	Overman et al., "An Annual Publication of Satisfactory Methods for the Preparation of Organic Chemicals." Organic Synthesis, vol. 71, pp. 48-55, 1993
	BZ	Snider et al., "Mn(III)-Based Oxidative Free Radical Cyclization of Unsaturated Ketones," Journal of Organic Chemistry, vol. 60, pp. 5376-5377, 1995
	CA	Fillon et al., "Self-Nucleation and Recrystallization of Isotactic Polypropylene (alpha Phase) Investigated by Differential Scanning Calorimetry," Journal of Polymer Science: Part B: Polymer Physics, vol. 31, pp. 1383-1393, 1993
	CB	Fillon et al., "Self-Nucleation and Enhanced Nucleation of Polymers. Definition of a Convenient Calorimetric "Efficiency Scale" and Evaluation of Nucleating Additives in Isotactic Polypropylene (alpha phase)," Journal of Polymer Science: Part B: Polymer Physics, vol. 31 pp. 1395-1504, 1993
Examiner:	Date Considered:	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.